Literature DB >> 19021846

Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas.

Sanjeev Chawla1, Laura Oleaga, Sumei Wang, Jaroslaw Krejza, Ronald L Wolf, John H Woo, Donald M O'Rourke, Kevin D Judy, Michael S Grady, Elias R Melhem, Harish Poptani.   

Abstract

BACKGROUND AND
PURPOSE: Preoperative differentiation of astrocytomas from oligodendrogliomas is clinically important, as oligodendrogliomas are more sensitive to chemotherapy. The purpose of this study was to assess the role of proton magnetic resonance spectroscopy in distinguishing astrocytomas from oligodendrogliomas.
METHODS: Forty-six patients [astrocytomas (n= 17) and oligodendrogliomas (n= 29)] underwent magnetic resonance imaging and multi voxel proton magnetic resonance spectroscopic imaging before treatment. Peak areas for N-acetylaspartate (NAA), creatine (Cr), choline (Cho), myo-inositol (mI), glutamate/glutamine (Glx), and lipids + lactate (Lip+Lac) were analyzed from voxels that exhibited hyperintensity on fluid-attenuated inversion recovery images and were normalized to Cr from each voxel. The average metabolite/Cr ratios from these voxels were then compared between astrocytomas and oligodendrogliomas. Receiver-operating curve analyses were used as measures of differentiation accuracy of metabolite ratios. A threshold value for a metabolite ratio was estimated by maximizing the sum of sensitivity and specificity.
RESULTS: A significant difference in mI/Cr was observed between astrocytomas and oligodendrogliomas (.50 +/- .18 vs. 0.66 +/- 0.20, P < .05). Using a threshold value of .56 for mI/Cr ratio, it was possible to differentiate oligodendrogliomas from astrocytomas with a sensitivity of 72.4% and specificity of 76.4%.
CONCLUSION: These results suggest that mI/Cr might aid in distinguishing oligodendrogliomas from astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19021846     DOI: 10.1111/j.1552-6569.2008.00307.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  12 in total

Review 1.  Non-invasive metabolic imaging of brain tumours in the era of precision medicine.

Authors:  Michelle M Kim; Abhijit Parolia; Mark P Dunphy; Sriram Venneti
Journal:  Nat Rev Clin Oncol       Date:  2016-07-19       Impact factor: 66.675

Review 2.  Glutamate and glutamine: a review of in vivo MRS in the human brain.

Authors:  Saadallah Ramadan; Alexander Lin; Peter Stanwell
Journal:  NMR Biomed       Date:  2013-10-04       Impact factor: 4.044

3.  Advanced MR imaging techniques in the evaluation of nonenhancing gliomas: perfusion-weighted imaging compared with proton magnetic resonance spectroscopy and tumor grade.

Authors:  Neslin Sahin; Elias R Melhem; Sumei Wang; Jaroslaw Krejza; Harish Poptani; Sanjeev Chawla; Gaurav Verma
Journal:  Neuroradiol J       Date:  2013-11-07

Review 4.  Standard clinical approaches and emerging modalities for glioblastoma imaging.

Authors:  Joshua D Bernstock; Sam E Gary; Neil Klinger; Pablo A Valdes; Walid Ibn Essayed; Hannah E Olsen; Gustavo Chagoya; Galal Elsayed; Daisuke Yamashita; Patrick Schuss; Florian A Gessler; Pier Paolo Peruzzi; Asim K Bag; Gregory K Friedman
Journal:  Neurooncol Adv       Date:  2022-05-26

Review 5.  Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.

Authors:  Sanjeev Chawla; Sultan Bukhari; Omar M Afridi; Sumei Wang; Santosh K Yadav; Hamed Akbari; Gaurav Verma; Kavindra Nath; Mohammad Haris; Stephen Bagley; Christos Davatzikos; Laurie A Loevner; Suyash Mohan
Journal:  NMR Biomed       Date:  2022-03-15       Impact factor: 4.478

6.  Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy.

Authors:  S Chawla; J Krejza; A Vossough; Y Zhang; G S Kapoor; S Wang; D M O'Rourke; E R Melhem; H Poptani
Journal:  AJNR Am J Neuroradiol       Date:  2013-01-31       Impact factor: 3.825

Review 7.  Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma.

Authors:  Fabrício Guimarães Gonçalves; Sanjeev Chawla; Suyash Mohan
Journal:  J Magn Reson Imaging       Date:  2020-03-19       Impact factor: 4.813

8.  Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.

Authors:  Gaurav Verma; Sanjeev Chawla; Suyash Mohan; Sumei Wang; MacLean Nasrallah; Sulaiman Sheriff; Arati Desai; Steven Brem; Donald M O'Rourke; Ronald L Wolf; Andrew A Maudsley; Harish Poptani
Journal:  NMR Biomed       Date:  2018-12-17       Impact factor: 4.044

9.  Characterization of metabolites in infiltrating gliomas using ex vivo ¹H high-resolution magic angle spinning spectroscopy.

Authors:  Adam Elkhaled; Llewellyn Jalbert; Alexandra Constantin; Hikari A I Yoshihara; Joanna J Phillips; Annette M Molinaro; Susan M Chang; Sarah J Nelson
Journal:  NMR Biomed       Date:  2014-03-05       Impact factor: 4.044

Review 10.  Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas.

Authors:  Filipa Martins; Luís G Gonçalves; Marta Pojo; Jacinta Serpa
Journal:  Biomolecules       Date:  2020-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.